Carole Colin

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

36h-index4.6kcitations134works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(73), Neuroblastoma Research and Treatments(18), MicroRNA in disease regulation(15), Meningioma and schwannoma management(14), Cancer, Hypoxia, and Metabolism(12)

Publications134 total

P12.51.B INTEGRATIVE MULTIOMIC ANALYSIS IDENTIFIES EIF4A1 AND CDK9 AS KEY THERAPEUTIC TARGETS IN OLIGODENDROGLIOMAS
Neuro-Oncology·2025Open Access
The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cells
Cancer Cell International·2025· 4 citedOpen Access
Reply to “The time has come for an integrated and multiscale grading system for oligodendrogliomas <i>IDH</i>-mutant and 1p/19q co-deleted mixing imaging and histomolecular parameters”
Neuro-Oncology·2025· 1 cited
The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cells
2025Open Access
Metabolic adaptation of myeloid cells in the glioblastoma microenvironment
Frontiers in Immunology·2024· 4 citedOpen Access
Phenotypic and epigenetic heterogeneity in <i>FGFR2</i> ‐fused glial and glioneuronal tumours
Neuropathology and Applied Neurobiology·2024· 1 citedOpen Access
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort
Neuro-Oncology·2024· 8 citedOpen Access
SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment
Cell Death and Disease·2024· 7 citedOpen Access
Author response for "Phenotypic and epigenetic heterogeneity in &lt;i&gt;FGFR2&lt;/i&gt;‐fused glial and glioneuronal tumours"
2024
Author response for "Phenotypic and epigenetic heterogeneity in &lt;i&gt;FGFR2&lt;/i&gt;‐fused glial and glioneuronal tumours"
2024
SMAC mimetics drive microglia phenotype and glioblastoma immune microenvironment
2024Open Access
Melanoma-inhibitor of apoptosis protein: a key driver of microglia phenotype and glioblastoma immune microenvironment
2024· 2 citedOpen Access
GD3 ganglioside is a promising therapeutic target for glioma patients.
Neuro-Oncology Advances·2024· 6 citedOpen Access
P12.09.B SMAC MIMETICS REPROGRAMS GLIOBLASTOMA IMMUNE LANDSCAPE AND POLARIZES MICROGLIA TOWARD A PRO-INFLAMMATORY ANTI-TUMORAL PHENOTYPE
Neuro-Oncology·2023Open Access
KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR TEMOZOLOMIDE IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH IDH-MUTANT, 1P/19Q CODELETED, GRADE 3 OLIGODENDROGLIOMA: ANALYSIS FROM THE POLA COHORT
Neuro-Oncology·2023· 3 citedOpen Access
Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms
EBioMedicine·2023· 19 citedOpen Access
Deciphering the Action of Neuraminidase in Glioblastoma Models
International Journal of Molecular Sciences·2023· 12 citedOpen Access
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion
Acta Neuropathologica Communications·2023· 27 citedOpen Access
Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms
2022· 2 citedOpen Access
MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression
Biomarker Research·2022· 5 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Dominique Figarella‐Branger(32), Karima Mokhtari(13), Olivier Chinot(11), Ahmed Idbaïh(10), Romain Appay(10), Corinne Bouvier(10), Alain Carpentier(9), François Ducray(9), Emmanuelle Uro‐Coste(9), Fréderic Fina(9), Philippe Métellus(8), L’Houcine Ouafik(8), Jean‐Yves Delattre(8), Didier Scavarda(8), Marc Sanson(7), A. Maues de Paula(7), Caroline Dehais(7), Claude‐Alain Maurage(7), Aurélie Tchoghandjian(7), Audrey Rousseau(6)